31 March 2025

Expanded PBS listing for empagliflozin

2 minute read

The SGLT2 inhibitor is now subsidised for people at increased cardiovascular risk without the need for an unmet glycaemic target.

This content is for members only.
Login Join Now

End of content

No more pages to load

Username

Password

Confirm Password

First Name

Last Name

Email Address

Full Name LEAVE THIS BLANK

What field do you work in?

Specialty:

Type of University work:

Industry Specialty:

Other:

First Name

Last Name

Address 1

Address 2

City

State

Postal Code

Country

Phone

Card Number

Expiration Date /

Security Code (CVC) (what's this?)

Processing...